CLAUSE · BACKTEST REPORT · HYPOTHETICAL PERFORMANCE
The AI supply chain
“buy companies and funds that benefit from AI: chips, hyperscalers, data-center REITs, the power they use, and AI ETFs in equal weight, hold every name for good, and trim each back to an equal slice on the first trading day of every quarter”
Tested over February 2022 to October 2026. On data sealed Oct 15, 2026. Published 15 October 2026.
The contract
- 1. Universe. Trade only NVDA, AVGO, AMD, TSM, MSFT, GOOGL, AMZN, META, EQIX, DLR, VST, CEG, SMH, AIQ.
- 2. Allocation. Set the target allocation of NVDA, AVGO, AMD, TSM, MSFT, GOOGL, AMZN, META, EQIX, DLR, VST, CEG and SMH to 7.14% each and set the target allocation of AIQ to 7.18%; reset to these weights on the first trading day of each quarter.
Equity vs SPY, dividends reinvested
Tear sheet
TOTAL
+297%
CAGR
+34.1%
VOL
28.7%
SHARPE
1.04
SPY SHARPE
0.61
BUY-AND-HOLD SHARPE
0.95
SORTINO
1.52
MAX DD
−34.8%
LONGEST DD
471 days
BETA
1.46
GROSS
99.4%
GROSS MAX
100%
NET
+99.4%
LONG
100%
SHORT
0.0%
TRADES
164
TURNOVER
26.0%
COST DRAG
0.0%
CAPACITY
$228,216 (AIQ)
FINAL VALUE
$397,019 from $100,000
Per-clause attribution
What each clause earned while its decision governed the portfolio, holds included; these add up to the total return. The second figure re-runs the backtest with that clause removed and shows how the result would change.
About these numbers
Window
Fills
Borrow
Every short pays 0.3% a year on the value of the position for each calendar day it is held. Where our data carries short interest, the rate steps up with short interest as a percent of shares outstanding, using the figure that was public before each session.
An assumption, not a record: we hold no historical borrow rates.
| Short interest | Borrow |
|---|---|
| 20% of shares outstanding or more | 12% a year |
| 10% of shares outstanding or more | 4% a year |
| 5% of shares outstanding or more | 1.5% a year |
| under 5%, or none on file | 0.3% a year |
Dividends
Margin
Delistings
Halts
Attribution
Hypothetical performance on historical data. The same contract on the same data and cost model reproduces this number exactly. Backtests are not indicative of future results.